- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases1000+
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases1000+
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- EGFR positive
- PR positive
- PR negative
- ER negative
- KRAS positive
- PD-L1 negative
- EGFR negative
- BRAF positive
- ALK negative
- p16 positive
- HLA-A positive
- IDH positive
- ALK positive
- CD20 positive
- BRCA1 positive
- BRCA2 positive
- MET positive
- HLA positive
- ROS1 positive
- CD19 positive
- MSI-H positive
- IDH negative
- ROS1 negative
- MYC positive
- TP53 positive
- p16 negative
- HLA negative
- dMMR positive
- BRAF negative
- HR positive
- NRAS positive
- PALB2 positive
- HPV positive
- RB1 negative
- HLA-A negative
- RB1 positive
- RET positive
- FLT3 positive
- BRCA positive
- MET negative
- NF1 positive
- PIK3CA positive
- BCL2 positive
- HPV negative
- NTRK positive
- ATM positive
- MGMT negative
- MMR positive
- ARID1A positive
- BCL6 positive
- CD22 positive
- KIT positive
- KRAS negative
- RAS positive
- CCND1 positive
- MGMT positive
- RAD51 positive
- ANA positive
- BRIP1 positive
- CD30 positive
- CHEK2 positive
- HbSS positive
- PD-1 positive
- Philadelphia Chromosome positive
- Anti-dsDNA positive
- BCR-ABL1 positive
- HRAS positive
- MLH1 positive
- MSH6 positive
- NTRK1 positive
- PMS2 positive
- PTEN positive
- RAS negative
- RET negative
- MSH2 positive
- MSI negative
- MSI positive
- MSI-H negative
- ctDNA positive
- AR positive
- ASXL1 positive
- CFTR positive
- FANCA positive
- HBV DNA negative
- HBV DNA positive
- MMR negative
- MSS positive
- NRAS negative
- PD-1 negative
- TP53 negative
- dMMR negative
- p53 positive
- BCR-ABL positive
- CD123 positive
- HBsAg negative
- HBsAg positive
- HR negative
- MSS negative
- NTRK negative
- RAD51C positive
- t(11;14) positive
- ABCA4 positive
- BAP1 positive
- BARD1 positive
- BRCA1 negative
- BRCA2 negative
- CD3 positive
- CD33 positive
- CDK12 positive
- CDK4 positive
- DLL3 positive
- FGFR2 positive
- FGFR3 positive
- GRN positive
- HPV16 positive
- KMT2A positive
- Ki-67 positive
- MECP2 positive
- MTAP positive
- NF2 positive
- NPM1 positive
- PDGFRA positive
- PH positive
- RAD51D positive
- RAD54L positive
- RF positive
- RUNX1 positive
- SMN1 positive
- T790M positive
- TERT positive
- TROP2 positive
- ZnT8 positive
- anti-Sm positive
- del(17p) positive
- t(14;16) positive
- AKT1 positive
- APOL1 positive
- BRCA negative
- CCNE1 positive
- CD4 positive
- CDK6 positive
- CHEK1 positive
- CLDN18.2 positive
- COL7A1 positive
- Complex karyotype positive
- DMD positive
- FANCL positive
- FGFR positive
- FLT3 negative
- FMR1 positive
- FRα positive
- GATA2 positive
- GPC3 positive
- HBB positive
- HBcAb negative
- HbSC positive
- HbSβ0-thalassemia positive
- IA-2 positive
- MLH1 negative
- MSH2 negative
- MSH6 negative
- NBN positive
- NF1 negative
- PMS2 negative
- RAF positive
- STK11 positive
- TROP2 negative
- t(14;20) positive
- t(4;14) positive
- t(9;22) positive
- AChR positive
- AKT negative
- APC positive
- ATR positive
- ApoE ε4 positive
- C5 positive
- CA-125 positive
- CCND2 positive
- CCND3 positive
- CD19 negative
- CD4 count positive
- CD5 positive
- CD70 positive
- CD8 positive
- CTNNB1 positive
- DMPK positive
- DNMT3A positive
- EBV positive
- EZH2 positive
- Ex19del positive
- FANCD2 positive
- FOLR1 positive
- HBcAb positive
- HCV RNA positive
- HRD positive
- IA-2A positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1927nm Fractional Thulium Laser Treatment
- Adalimumab
- Adjuvant Chemotherapy without Concurrent Biologic/Targeted Therapy
- Adjuvant Therapy (except reconstruction)
- Adverse Event from Previous Treatment (Excluding Alopecia, Cutaneous Toxicity, Peripheral Neuropathy, Fatigue Grade ≤ 2)
- Allogeneic Hematopoietic Cell Transplantation
- Alopecia from Prior Anti-Cancer Therapy
- Anemia from Prior Anti-Cancer Therapy
- Anti-HER2 Therapy (if HER2 overexpression)
- Anti-Seizure Medications (up to 2 types)
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
7795 trials
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a 4-drug combo vs. a 3-drug combo to see if the former is more effective in shrinking cancer or preventing its return.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests two drugs, MRTX849 and pembrolizumab, in patients with advanced lung cancer who have a specific genetic mutation. MRTX849 targets the mutation to stop cancer growth, while pembrolizumab boosts the immune system to fight the cancer. The study aims to see how well these treatments work alone and together.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares shorter chemo-immunotherapy without anthracyclines to usual chemo-immunotherapy to treat early-stage triple negative breast cancer. Drugs used to stop cancer cells from growing/dividing & kill them, plus an immunotherapy drug.
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial tests a combination of two drugs to see if they're better than one drug at preventing breast cancer from coming back in patients with high risk, HER2 positive breast cancer.
Efficacy & Safety Awards
Pivotal Trial
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test new targeted cancer therapies against standard of care therapy in order to find more effective treatments.
Efficacy & Safety Awards
No Placebo-Only Group
Get notified when new Cutaneous Melanoma trials are postedWe'll send you an email whenever new trials are posted
Kingman, KS (<20 mi)
Recruiting
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying nivolumab and ipilimumab to see how well they work with or without sargramostim in treating patients with stage III-IV melanoma that cannot be removed by surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial studies crizotinib for patients with stage IB-IIIA NSCLC who have had surgery and have an ALK fusion mutation. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working.
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying how well paclitaxel, trastuzumab, and pertuzumab work in eliminating chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery.
Efficacy & Safety Awards
No Placebo-Only Group
Kingman, KS (<20 mi)
Recruiting
Phase 21 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is studying a combination of drugs as a possible treatment for rare genitourinary tumors.
Efficacy & Safety Awards
No Placebo-Only Group
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a medication called Pegozafermin to see if it can lower high levels of fats in the blood in people with severe hypertriglyceridemia. These patients have very high triglyceride levels, which can lead to serious health issues. The medication aims to reduce these fat levels to improve their health.
Efficacy & Safety Awards
Pivotal Trial
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if ubrogepant is safe and effective for young people with migraines. Ubrogepant is a medication taken by mouth to treat migraine headaches. It works by blocking a protein in the brain that causes migraine pain. The study focuses on children and adolescents who suffer from migraines.
Efficacy & Safety Awards
Pivotal Trial
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing lepodisiran, a medication given as an injection under the skin. It targets people with high levels of lipoprotein(a) who have cardiovascular disease or are at risk of heart attack or stroke. The medication works by lowering lipoprotein(a) levels to reduce the risk of these cardiovascular events.
Efficacy & Safety Awards
Pivotal Trial
Hutchinson, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test a new medication called Baxdrostat with Dapagliflozin to see if it can improve kidney health and reduce the risk of heart problems in people with chronic kidney
Efficacy & Safety Awards
Pivotal Trial
Hutchinson, KS (<50 mi)
Recruiting
Phase 2
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test the effectiveness and safety of a drug called amlitelimab in adults with non-responsive celiac disease who are on a gluten-free diet. The study will compare amlit
Get notified when new Small Cell Lung Cancer trials are postedWe'll send you an email whenever new trials are posted
Wichita, KS (<50 mi)
Recruiting
Phase 33 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
Efficacy & Safety Awards
Pivotal Trial
Verified Trial Data
No Placebo-Only Group
Wichita, KS (<50 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to study the safety and effectiveness of a new drug called ubrogepant in treating menstrual migraines. Menstrual migraines are headaches that occur before, during, or after
Efficacy & Safety Awards
Pivotal Trial
1
2
3
…50